BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22772426)

  • 1. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
    Keizman D; Maimon N; Gottfried M
    Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic hormone refractory prostate cancer: new treatment horizon].
    Keizman D; Maimon N; Gottfried M
    Harefuah; 2012 Sep; 151(9):545-9, 555, 554. PubMed ID: 23367751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F; Gallick GE; Logothetis CJ; Corn PG
    J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 10. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targeted therapies for prostate cancer.
    Macfarlane RJ; Chi KN
    Urol Clin North Am; 2010 Feb; 37(1):105-19, Table of Contents. PubMed ID: 20152524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH; Kockler DR
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting advanced prostate cancer.
    Fillon M
    J Natl Cancer Inst; 2011 Dec; 103(23):1733. PubMed ID: 22100582
    [No Abstract]   [Full Text] [Related]  

  • 20. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.